The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

被引：487
|
作者：
Yuan, Min [1 ,2 ]
Huang, Li-Li [1 ,2 ]
Chen, Jian-Hua [1 ,3 ]
Wu, Jie [3 ,4 ]
Xu, Qing [1 ,2 ]
机构：
[1] Tongji Univ, Dermatol Hosp, Dept Oncol, Sch Med, Shanghai 200443, Peoples R China
[2] Tongji Univ, Shanghai Peoples Hosp 10, Dept Oncol, Sch Med, Shanghai 200072, Peoples R China
[3] Univ Oklahoma, Hlth Sci Ctr, Peggy & Charles Stephenson Canc Ctr, Oklahoma City, OK 73104 USA
[4] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA
来源：
SIGNAL TRANSDUCTION AND TARGETED THERAPY | 2019年 / 4卷 / 1期
基金：
中国国家自然科学基金;
关键词：
EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE INHIBITORS; ANTI-HER3; MONOCLONAL-ANTIBODY; NIVOLUMAB PLUS IPILIMUMAB; RECEPTOR GENE-MUTATIONS; RANDOMIZED PHASE-III; OPEN-LABEL; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; EGFR MUTATIONS;
D O I：
10.1038/s41392-019-0099-9
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Lung cancer is one of the most common cancer in the world. In 2018, there were over 2 million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer. Targeted therapy has emerged as an important mean of the disease management for patients with non-small-cell lung cancer (NSCLC). Herein, we review and analyze recent literature, discuss the targeting pathways and ongoing clinical trials in lung cancer. Chemotherapy is no longer the best available treatment for all patients. Therapeutic decisions should be guided by an understanding of the molecular features of patient's tumor tissues. The future gains will likely emerge from finding optimal ways of combining targeted therapy, immunotherapy, and chemotherapy.
引用
收藏
页数：14
相关论文
共 50 条
  • [1] Resistance to molecularly targeted therapy in non-small-cell lung cancer
    Asao, Tetsuhiko
    Takahashi, Fumiyuki
    Takahashi, Kazuhisa
    RESPIRATORY INVESTIGATION, 2019, 57 (01) : 20 - 26
  • [2] Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)
    Mina, Syeda A.
    Shanshal, Mohamed
    Leventakos, Konstantinos
    Parikh, Kaushal
    CANCERS, 2025, 17 (03)
  • [3] New and emerging targeted treatments in advanced non-small-cell lung cancer
    Hirsch, Fred R.
    Suda, Kenichi
    Wiens, Jacinta
    Bunn, Paul A., Jr.
    LANCET, 2016, 388 (10048) : 1012 - 1024
  • [4] Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer
    Giovannetti, Elisa
    Erdem, Lale
    Olcay, Efnan
    Leon, Leticia G.
    Peters, Godefridus J.
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2011, 16 : 116 - 130
  • [5] Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer
    Sa, Huanlan
    Song, Peng
    Ma, Kewei
    Gao, Yong
    Zhang, Li
    Wang, Deqiang
    ONCOTARGETS AND THERAPY, 2019, 12 : 8151 - 8159
  • [6] Molecular targeted therapy of patients with non-small-cell lung cancer
    Stencel, Katarzyna
    Swiniuch, Daria
    Ramlau, Rodryg
    ONCOLOGY IN CLINICAL PRACTICE, 2019, 15 (06): : 289 - 296
  • [7] The emerging treatment landscape of advanced non-small cell lung cancer
    Economopoulou, Panagiota
    Mountzios, Giannis
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (08)
  • [8] Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer
    Li, Shenduo
    Correia, Guilherme Sacchi de Camargo
    Wang, Jing
    Manochakian, Rami
    Zhao, Yujie
    Lou, Yanyan
    CANCERS, 2023, 15 (11)
  • [9] Gefitinib for the treatment of non-small-cell lung cancer
    Campbell, Lynn
    Blackhall, Fiona
    Thatcher, Nicholas
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (08) : 1343 - 1357
  • [10] Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer
    Halliday, Patrick R.
    Blakely, Collin M.
    Bivona, Trever G.
    CURRENT ONCOLOGY REPORTS, 2019, 21 (03)
12345